TrialCancer chemotherapy and pharmacology2021

A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.

Takashi Eto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.